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Abstract—Ultrasound (US) and microbubble (MB) gene 
delivery has attracted growing interest as a clinically applicable 
gene therapy (GT). Though preclinical studies have investigated 
the system in various tissues, there is limited research in 
targeting the placenta. This is a potential therapeutic strategy 
for preeclampsia (PE), which has an underlying genetic basis 
and ineffective management strategies. Differentially expressed 
placental microRNAs (miRNAs) in PE may represent suitable 
targets for GT. Microbubbles (SonoVue) and plasmid (pGL3 or 
pGL4.13) were administered systemically to CD1 mice, followed 
by exposure of the heart to US (B-mode, H14, 1.8 M.I., 1cm focal 
depth, 2 minutes), using Siemens Acuson Sequoia-512 system 
and 15L8 probe. Luciferase assays were performed to evaluate 
gene transfection. Significantly differentially expressed 
placental miRNAs in PE patients were identified as candidate 
miRNAs based on detection by ≥3 screening studies. Expression 
of candidate miRNAs was measured by qRT-PCR in PE rat 
model placentas. In trial 1, low levels of luciferase activity were 
detected in the heart of treatment mouse 1, 2 and 3. In trial 2, 
luciferase activity was evident in the atria of treatment mouse 2. 
In trial 3, higher luciferase activity was detected in the ventricles 
of the treatment mouse and activity was also detected in the 
atria. The literature review identified eight candidate miRNAs. 
MiR-223 (1.46-fold increase) and miR-181a (0.81-fold decrease) 
were significantly differentially expressed in PE rat model 
placentas. MiR-223 and miR-181a may represent targets for US 
and MB gene delivery. Future studies will apply the US and MB 
gene delivery protocol for translation to targeting the placenta 
in our PE rodent model. 
Keywords—Ultrasound, Microbubbles, Gene Therapy, 
Preeclampsia, Placenta, MicroRNAs 
I. INTRODUCTION 
Substantial progress has been made in the field of gene 
therapy (GT), with six therapies approved since 2012 [1] and 
the number of clinical trials continuing to rise [2]. GT is 
defined as the transfer of genetic material into cell nuclei as a 
treatment for diseases with a genetic component. To target 
desired cells and achieve therapeutically relevant gene 
transfer for a sufficient time period, gene delivery systems are 
employed, typically: viral or non-viral [3]. Viral-based 
systems generally lead to higher transduction efficiencies but 
carry serious safety risks [3]. Non-viral systems are 
considered safer but suffer lower transfection efficiencies; 
thus, physical and/or chemical methods are often used to 
enhance transfection levels [3]. Despite technological 
advancements, the majority of trials remain in phase I and I/II 
[2]. Hence, preclinical proof-of-concept studies are crucial to 
the development of safe and effective gene delivery systems. 
Ultrasound (US) and microbubble (MB) gene delivery has 
attracted growing interest as a clinically applicable GT. In 
conjunction with plasmid DNA or other nucleic acid 
complexes, US and MB gene delivery is a non-viral physical 
method for enhancing gene transfection. In preclinical 
studies, the delivery system has been used to target various 
tissues and therapeutically relevant gene transfer levels have 
been reported in numerous diseases [4, 5]. However, there is 
limited research in targeting the placenta. 
Preeclampsia (PE) is a pregnancy disorder, characterized 
by new hypertension and significant proteinuria at or after 20 
weeks of pregnancy [6].  It is a leading cause of maternal and 
perinatal morbidity and mortality [6]. Delivery resolves PE’s 
complications; however, preterm deliveries increase the risk 
of foetal morbidity and mortality [6]. There are treatments 
that target maternal complications to delay delivery although 
these carry safety and efficacy issues [7-9]. Hence, there is a 
need for novel treatment strategies that can prevent PE.   
PE is now recognised as a complex genetic disorder, with 
numerous candidate genes identified [10] and growing 
evidence of altered placental microRNA (miRNA) expression 
profiles in PE patients [11]. MiRNAs are short non-coding 
RNAs involved in post-transcriptional gene regulation. In-
vitro and in-vivo studies have demonstrated their role in 
placental development and function as well in the pathology 
of PE arising from their aberrant expression [12, 13]. 
The aims of this study were 1) to develop a protocol for 
US and MB gene delivery with potential applicability to the 
placenta by conducting proof-of-concept trials to demonstrate 
site-specific gene transfection in the hearts of CD1 mice and 
2) to identify differentially expressed placental miRNAs in 
3rd trimester PE patients, through a literature review, and 
compare their expression with that of PE rodent model 
recently published by our group [14]. 
II. METHODS 
A. Plasmid DNA 
The pGL3-Control Vector (Promega, Southampton, UK), 
a plasmid expressing luc+, a modified firefly luciferase gene, 
was transformed into MAX Efficiency™ DH5α™ Competent 
Cells (ThermoFisher, Paisley, UK). pGL3 was isolated and 
purified using InvitrogenTM PureLinkTM HiPure Expi Plasmid 
Megaprep Kit, according to the Revision A.0 User Guide 
(ThermoFisher, Vilnus, Lithuania). From a glyceral stock, the 
pGL4.13[luc2/SV40] Vector, a plasmid expressing luc2, a 
synthetically engineered luciferase gene, was isolated and 
purified using InvitrogenTM PureLinkTM HiPure Expi Plasmid 
Megaprep Kit, according to the Revision A.0 User Guide 
(ThermoFisher, Vilnus, Lithuania). Plasmid DNA 
concentration was measured using NanoDrop 1000 
Spectrophotometer (ThermoFisher, Paisley, UK) and adjusted 
with 1X Tris-EDTA (TE) buffer to obtain 4 µg/µL. 
B. Plasmid DNA and Microbubble Suspension 
SonoVue (Bracco International B.V., Amsterdam, 
Netherlands) was prepared according to the manufacturers 
instruction at double concentration, by discarding half the 
volume (2.5 ml) of sodium chloride (0.9%). 150 μL of MBs 
and 50 μL of plasmid DNA were pipetted into a 
microcentrifuge tube, making up a 200 μL injectable 
suspension per animal. 
C. In-vivo Transfection 
All animal work was carried out in accordance with the 
Animals (Scientific Procedures) Act 1986. Female, 6-8 week 
old, CD-1 mice (25g-35g) were anaesthetised with 5% 
isofluorane and maintained on 1.5% isofluorane on a 
homeothermic mat. Mice were placed in a supine position, 
and, over an area of 1.5 cm2 above the ribcage, hair was 
removed by shaving and depilatory cream, and US gel was 
applied. For all US scans, Acuson Sequoia-512 ultrasound 
system (Siemens pls, Surrey, UK) and 15L8 linear array 
transducer probe with a frequency range of 7-15 MHz was 
used. B-mode output was used for organ location. The 
transducer was placed on the shaved area overlying the heart 
to obtain a parasternal long axis view (14 MHz, 0.6 
mechanical index (MI), and 10 mm focal depth). Once the 
organ was located and appropriate view obtained, the probe 
was held in a fixed position and set to harmonic imaging (H14 
MHz, 1.8 MI, and 10 mm focal depth). For treatment mice, 
the plasmid DNA and MB suspension was gently stirred with 
a 25G needle (Terumo, Leuven, Belgium) and drawn into a 
syringe (Table 1). The suspension was injected slowly into 
the tail vein over a 60 second period. This was immediately 
followed by an additional 2 minutes of US application. The 
probe was then removed and the mouse was recovered. 
Negative control mice underwent the same procedure, 
receiving 1X phosphate buffered saline (PBS) / MB 
suspension in place of plasmid DNA (Table 1). Positive 
control mice were anaesthetised with 5% isofluorane and 
maintained on 1.5% isofluorane on a homeothermic mat. An 
area of 1 cm2 over the left gracilis muscle was shaved and 
plasmid DNA / MB suspension was administered into the 
gracilis muscle by multiple intramuscular injections (Table 
1). The mouse was then recovered. All mice were sacrificed 
after three days, and the hearts and left gracilis muscles were 
dissected and snap frozen in liquid nitrogen. 
 
TABLE I.  EXPERIMENTAL DESIGN OF IN-VIVO TRIALS 
Trial 
(plasmid) 
Experimental Design 
Animal (n number) 
Plasmid 
volume (µL) 
Microbubble 
volume (µL) 
1 (pGL3) Treatment (3) 50 150 
1 (pGL3) Negative Control (1) 200 µL PBS 0 
1 (pGL3) Positive Control (1) 50 0 
2 (pGL3) Treatment (3) 50 150 
2 (pGL3) Negative Control (1) 160 µL PBS 40 
2 (pGL3) Positive Control (1) 17 33 
3 (pGL4.13) Treatment (1) 50 150 
3 (pGL4.13) Negative Control (1) 150 µL PBS 40 
3 (pGL4.13) Positive Control (1) 50 0 
D. Luciferase Assay 
Luciferase protein activity was measured using the 
luciferase assay reporter system (Promega, Southampton, 
UK). For trial 1 and 2, a mortar and pestle were used for tissue 
disruption, and tissue was lysed by adding 1:20 (w/v) tissue 
protein extraction reagent (T-PER) (ThermoFisher, 
Loughborough, UK) and placing samples on ice for 1 hour on 
a shaker. Samples were centrifuged at 10,000g for 5 minutes. 
For trial 3, a mortar and pestle were used for tissue disruption, 
and tissue was homogenized in 1:20 (w/v) T-PER two times 
for 30 seconds at 30kHz with bead-milling in TissueLyser 
(Qiagen, Haan, Germany). Tissue was subject to three freeze 
thaw cycles and centrifuged at 10,000g for 5 minutes. All 
reactions were set-up on 96 well-plates with 100 μL 
luciferase assay reagent (Promega, Southampton, UK) and 20 
μL of sample supernatant. Luciferase activity was measured 
in counts per second for 10 seconds using the PerkinElmir 
2030 plate reader (Perkin Elmer, Singapore, Singapore). 
E. Protein Assay 
Total protein concentration of mouse tissue samples used 
in the luciferase assay was measured using the Pierce BCA 
protein assay (ThermoFisher, Loughborough, UK). The 
protein assay was performed according to the manufacturer’s 
protocol (ThermoFisher, Loughborough, UK). 
F. Literature Review 
A literature review was conducted using PubMed database 
to identify studies between January 1990 and March 2018 
with the following search terms: ‘pre-eclampsia’, 
‘preeclampsia’, ‘miR’, and ‘microRNA’. The search strategy 
was to identify screening studies investigating differentially 
expressed placental miRNAs in 3rd trimester preeclamptic 
patients compared to normotensive controls. Data of 
miRNAs was collected based on significance defined by the 
study (e.g. p-value and fold change).  
Significantly differentially expressed placental miRNAs 
detected by three or more screening studies were identified. 
In turn, selected miRNAs were assessed for presence of rat 
orthologs, studies supporting a role for the miRNA in the 
placenta, and validation in placenta in at least one either fully 
or partially independent cohort. Selected miRNAs were 
considered  as candidates if they met all three criteria. 
G. Rat Placental MicroRNAs 
Whole placental tissue was collected on gestational day 18 
from four control (saline treated) and four preeclamptic (1000 
ng/kg/min Ang II treated) spontaneously hypertensive stroke 
prone (SHRSP) rats, in which Ang II has been administered 
from gestational day 10.5 to induce superimposed PE [14]. 
H. RNA Extraction 
RNA extractions were performed using miRNeasy mini 
kits (QIAGEN, Manchester, UK), according to the 
manufacturer’s protocol December 2014. Rat placental tissue 
was homogenised in QIAzol Lysis Reagent twice for 30 
seconds at 25 kHz with Polytron PT2100 Benchtop 
Homogenizer with 3mm dispersing aggregates 
(KINEMATICA, Luzern, Switzerland). 
I. MicroRNA Reverse Transcription 
Reverse transcription of rat RNA templates was 
performed with TaqMan™ MicroRNA Reverse 
Transcription Kit (ThermoFisher, Vilnus, Lithuania) 
according the manufacturer’s protocol TaqMan® Small RNA 
Assays USER GUIDE, using a template specific stem loop 
primer supplied with the Applied BiosystemsTM 20X 
TaqManTM MicroRNA Assays (Table 2). All reactions were 
set-up in 96 well plates (Starlab, Milton Keynes, UK) and 
thermocycling was performed on the MJ research Tetrad 
PTC-225 Thermal Cycler (MJ research, Ramsey, USA).  
TABLE II.  TAQMAN™ MICRORNA ASSAY NAMES AND IDS 
Assay name Assay ID 
Rno-miR-363-3p 001355 
Hsa-miR-223 000526 
Hsa-miR-210 000512 
Hsa-miR-195 000494 
Hsa-miR-181a 000480 
Hsa-miR-30a-5p 000417 
Hsa-miR-29b 000413 
Hsa-miR-16 000391 
U87 001712 
J. MicroRNA TaqMan qRT-PCR 
Amplification of rat cDNA was performed with TaqmanTM 
Universal Master Mix II, No UNG (ThermoFisher, Carlsbad, 
USA), according to the manufacturer’s protocol (PN 
4428173B). All reactions used Applied BiosystemsTM 20X 
TaqManTM MicroRNA Assays (Table 2) in simplex. All 
reactions were set-up in 384 well-plates (ThermoFisher, 
Loughborough, UK) and thermal cycling was performed with 
QuantStudio 12K Flex Real-Time PCR System. 
K. Statistical Analysis 
Graphpad Prism 4 was used to analyse all data sets. 
Luciferase assay data is expressed as mean luciferase activity 
(counts per second (CPS) / μg of protein) ± SD; n=3 (trial 1 
and 3) and n=4 (trial 2) technical replicates per group. For the 
protein assay, linear regression was performed on standards 
to obtain a standard curve. Protein concentration of samples 
was determined from the standard curve. Taqman qRT-PCR 
was analysed by relative quantification (RQ) using the 
comparative Ct method; n=4 per group. Data are shown as 
mean RQ (RQ min–max) ± S.E.M and were analysed by 
unpaired t-test. A value of p<0.05 was considered significant. 
III. RESULTS 
A. In-vivo Trials 
In trial 1, low levels of luciferase activity were detected 
in the heart of treatment mouse 1 (2.56±1.95 CPS/μg of 
protein), treatment mouse 2 (0.66±0.73 CPS/μg of protein), 
and treatment mouse 3 (2.05±2.08 CPS/μg of protein), 
compared to background luciferase activity in the heart of the 
negative control mouse (0.53±0.57 CPS/μg of protein) (Fig. 
1A). The highest level of luciferase activity was detected in 
the gracilis muscle of the positive control mouse (21.2±5.90 
CPS/μg of protein) (Fig. 1B). 
 
Fig. 1. Trial 1 luciferase activity in tissue from the three treatment mice, 
positive control mouse, and negative control mouse in A) heart and B) 
gracilis muscle. Data are shown as mean counts per second (CPS) / μg of 
protein ± SD. n=3 technical replicates. 
In trial 2, of the heart tissue samples examined (i.e. atria 
and ventricles), only the atria of treatment mouse 2 
(14.6±19.5 CPS/μg of protein) demonstrated a signal higher 
than background when compared with the atria and ventricles 
of the negative control mouse (7.77±2.79 and 0.49 ± 0.05 
CPS/μg of protein, respectively) (Fig. 2A). Luciferase 
activity was detected in the gracilis muscle of the positive 
control mouse (6.17±4.51 CPS/μg of protein) (Fig. 2B). 
 
Fig. 2. Trial 2 luciferase activity in tissue from the three treatment mice, 
positive control mouse, and negative control mouse in A)  atria and 
ventricles and B) gracilis muscle. Data are shown as mean counts per second 
(CPS) / μg of protein ± SD. n=4 technical replicates. 
In trial 3, luciferase activity was detected in the 
ventricles and atria of the treatment mouse (42.2±4.39 and 
2.51±0.77 CPS/μg of protein, respectively) (Fig. 3A), greater 
than background activity in the ventricles and atria of the 
negative control mouse (0.29±0.38 and 1.49±0.53 CPS/μg of 
protein, respectively) (Fig 3A). Highest luciferase activity 
was detected in the gracilis muscle of the positive control 
mouse (1,330.3±643.8 CPS/μg of protein) (Fig. 3B). 
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 Fig. 3. Trial 3 luciferase activity in tissue from the treatment mouse, 
positive control mouse, and negative control mouse in A)  atria and  
ventricles and B) gracilis muscle. Data are shown as mean counts per second 
(CPS) / μg of protein ± SD. n=3 technical replicates. 
B. Literature Review 
14 miRNAs were detected by three or more screening 
studies (miR-584-5p, -542-3p, -363-3p, 301a-3p, -223-3p, -
214-3p, -210-3p, -195-5p, -193b-3p, -181a-5p, -30a-5p, -29b-
3p, -16-5p, and -1-3p) (data not shown). Of the 14 miRNAs, 
eight were selected as candidates (miR-363-3p, -223-3p, -210-
3p, -195-5p, -181a-5p, -30a-5p, 29b-3p, and -16-5p) based on 
presence of a rat ortholog, previous studies supporting a role 
for the miRNA in the placenta, and validation of the miRNA 
in the placenta in an independent cohort (data not shown). 
C. Placental MicroRNA Expression in a PE Rat Model 
There was a significant increase in the relative expression 
of miR-223 (1.46-fold (0.12-0.13), *p<0.05) (Fig. 4A) and 
significant decrease in miR-181a (0.76-fold (0.04-0.04), 
*p<0.05) (Fig. 4B) in the placenta of the PE rat model. All 
other miRNAs did not reach significance (data not shown). 
 
Fig. 4. Taqman qRT-PCR for evaluation of mRNA expression in the 
placenta of a PE rat model of candidate miRNAs A) mir-223 and B) mir-
181a.          control,         PE model. Data are shown as mean RQ±S.E.M, 
n=4 per group, analysed using unpaired t-test, *p<0.05. 
IV.  DISCUSSION 
The purpose of this study was to develop a protocol for US 
and MB gene delivery by conducting proof-of-concept trials 
to demonstrate site-specific gene transfection. Following 
adaptations to the protocol, moderate site-specific gene 
transfection was evident in the ventricles of a treatment 
mouse, notably distinguishable from background activity. 
This provides a basic gene delivery protocol with potential 
applicability to the placenta. Of eight candidate miRNAs, two 
miRNAs were significantly differentially expressed in PE rat 
model placentas. MiR-181a and miR-223 are potential targets 
for US and MB gene delivery to the placenta in PE. 
Three previous US and MB gene delivery studies have 
utilized the Acuson Sequoia-512 system and 15L8 probe with 
SonoVue MBs and plasmid DNA injected via the tail vein to 
target the heart in mice, demonstrating successful gene 
transfection [15-17]. In trial 1, low levels of gene transfection 
with high variation were seen in the hearts of all treatment 
mice. Previous US and MB gene delivery studies targeting 
the heart have found gene transfection differs between 
regions of the heart [18, 19]. Hence, for trial 2, hearts were 
dissected into the atria and ventricle, with the aim of reducing 
variation. In trial 2, gene transfection was detected in the atria 
of treatment mouse 2. Past studies have found greater 
transfection efficiency in the ventricles compared to the atria. 
One study in rats found lowest transfection in the atria 
compared to the ventricles when holding the probe stationary 
or in motion [18]. In a study in mice, where the probe was 
held stationary, lower gene transfection efficiency was also 
seen in the atria compared to the ventricles [19]. High 
expression in the atria in trial 2 may be attributed to probe 
placement. In the current study, the probe was held stationary 
in a parasternal long axis view, following a previous protocol 
[17]. This view primarily consists of the left ventricle, though 
the left atrium and a portion of the right ventricle are within 
view. Human technical variability in probe placement and 
biological variability in mice may have contributed to 
differences in the targeted region. In turn, probe placement 
was carefully considered in the subsequent trial.  
As seen in past studies [18, 19], in trial 3, a moderate level 
of gene transfection was evident in the ventricles of the 
treatment mouse and lower levels in the atria. In comparison 
to trial 1 and 2, gene transfection efficiency was notably 
higher in trial 3. Though previous studies have shown 
successful gene transfection with pGL3 in a variety of organs 
and species [20, 21], the improved gene transfection levels in 
trial 3 likely reflects use of pGL4.13 in place of pGL3. pGL3 
vectors contain the luciferase gene luc+[22], while pGL4 
vectors harbour a synthetically engineered luciferase gene, 
luc2, that displays enhanced expression [23]. Finally, reduced 
variation and background signals likely reflect changes made 
to the luciferase assay in terms of tissue homogenisation. 
MiR-181a and -223 may represent suitable targets for GT 
applications in PE, with in-vitro studies demonstrating their 
role in modulating properties of placental cells. MiR-181a 
has shown to inhibit trophoblast migration and invasion [24] 
and mesenchymal stem cell proliferation [25] and miR-223 
has shown to promote trophoblast survival and invasion [32]. 
However, screening studies consistently report miR-181a is 
upregulated in placentas of PE patients [26-30], in contrast to 
the downregulation of miR-181a seen in the PE rat model. 
This may be attributed to the types of PE under study, 
supported by previous studies showing differences in miRNA 
expression between subtypes [27, 31]. For miR-223, 
screening studies in placentas of PE patients have reported 
both an upregulation [33-35] and downregulation [27, 28, 36-
39]. A study by our group is extending investigations to 
include miRNA candidate studies in PE patients and examine 
miRNA expression between rat placental layers in order to 
elucidate the reasons behind the contrasting findings. 
Overall, this study provides a proof-of-concept protocol 
for potential applicability to the placenta, with results 
showing site-specific gene transfection in the heart of a 
treatment mouse. This study also identifies potential miRNAs 
of interest as targets for GT applications. Targeting placental 
miRNAs represents a novel application of US and MB gene 
delivery and potentially new treatment strategy for PE. 
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